Addus HomeCare (ADUS) Continues To Execute, Reit Buy At Jefferies

Jefferies analyst, Brian Tanquilut, reiterated his Buy rating on shares of Addus HomeCare (NASDAQ: ADUS) after Q4 Revenue of $139.8M beat consensus of $139.4M. Proift was strong as well with Q4 EBITDA of $12.3M vs consensus of $12.2M and EPS of $0.55 beat consensus of $0.49. The profit upside was primarily driven by lower D&A and interest expense.

Even though the profit beat was slight, the analyst sees 3 reasons the shares warrant a Buy rating: 1) demand for personal care services continues to expand, 2) management deploys capital toward M&A, 3) the integration of recent acquisitions yields scale, efficiency gains, and enhanced market share.

No change to the price target of $75.

For an analyst ratings summary and ratings history on Addus HomeCare click here. For more ratings news on Addus HomeCare click here.

Shares of Addus HomeCare closed at $64.27 yesterday.

You May Also Be Interested In

• Jefferies Upgrades Five Below (FIVE) to Buy
• Kotak Upgrades Jyothy Laboratories Ltd. (JYL:IN) to Buy (1)
• JPMorgan Upgrades Astral Ltd (ASTRA:IN) to Overweight